Education
About Us
Working with TipRanks
Follow Us
GDOC - ETF AI Analysis
Top Page
Goldman Sachs Future Health Care Equity ETF (GDOC)
Rating:70Neutral
Price Target:―
Positive Factors
Established Health Care Leaders
Several top holdings like Johnson & Johnson and Thermo Fisher have shown solid recent performance, helping support the ETF’s returns.
Focused Health Care Exposure
With almost all assets in the health care sector, the fund gives targeted access to a specific growth theme rather than spreading across many unrelated industries.
Recent Performance Momentum
The ETF has delivered steady gains over the past three months and year-to-date, indicating improving short-term momentum.
Negative Factors
High Sector Concentration
Nearly all assets are in health care, so the fund could be hit hard if this sector faces regulatory or market pressure.
Mixed Top Holding Performance
Several large positions, including Boston Scientific, Intuitive Surgical, and AstraZeneca, have recently lagged, which can drag on overall returns.
Relatively High Expense Ratio
The fund’s fee is on the higher side for an ETF, which can eat into long-term returns compared with lower-cost alternatives.
GDOC vs. SPDR S&P 500 ETF (SPY)
AUM20.65M
RegionGlobal
Expense Ratio0.75%
Beta0.70
IssuerGoldman Sachs
Inception DateNov 09, 2021
Dividend Yield0.33%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume5,371
30 Day Avg. Volume1,604
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
42.61Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering40
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GDOC Summary
GDOC is the Goldman Sachs Future Health Care Equity ETF, focused on companies using technology to change how health care is delivered, rather than tracking a traditional index. It invests mainly in U.S. health care and health tech firms, including well-known names like Eli Lilly and Johnson & Johnson, along with makers of medical devices and diagnostic tools. Someone might invest in GDOC to seek long-term growth from advances in digital health, biotech, and medical innovation. A key risk is that it is heavily concentrated in the health care sector, so its price can rise or fall sharply with that industry.
How much will it cost me?The Goldman Sachs Future Health Care Equity ETF (GDOC) has an expense ratio of 0.75%, meaning you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on specialized health care technology companies that require more research and expertise to select.
What would affect this ETF?The Goldman Sachs Future Health Care Equity ETF (GDOC) could benefit from increasing demand for health care technology, driven by advancements in telemedicine, biotech, and medical devices, as well as global aging populations requiring innovative solutions. However, it may face challenges from regulatory changes in the health care sector, fluctuating interest rates affecting growth-focused companies, and potential competition or setbacks in technological adoption. Its global exposure and focus on leading companies like Eli Lilly and Boston Scientific provide both opportunities and risks tied to the broader health care industry trends.
GDOC Top 10 Holdings
GDOC is firmly hitched to the future of health care, with Eli Lilly and Johnson & Johnson acting as the main engines, both rising on solid earnings and steady demand for their drug pipelines. Thermo Fisher is also pulling its weight, benefiting from ongoing demand for lab tools and diagnostics. On the flip side, Boston Scientific and Intuitive Surgical have been lagging lately, taking some shine off returns, while Abbott looks stuck in neutral. The fund is heavily concentrated in health care innovators, with a mostly U.S. tilt but a notable global flavor through names like AstraZeneca.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 11.99% | $2.48M | $987.61B | 19.67% | 72 Outperform | |
| Johnson & Johnson | 7.83% | $1.62M | $574.95B | 53.70% | 78 Outperform | |
| Thermo Fisher | 6.67% | $1.38M | $205.42B | 1.63% | 72 Outperform | |
| AstraZeneca | 5.99% | $1.24M | £215.33B | 21.85% | 80 Outperform | |
| Boston Scientific | 5.66% | $1.17M | $109.92B | -29.92% | 79 Outperform | |
| Merck & Company | 4.86% | $1.00M | $292.01B | 35.95% | 80 Outperform | |
| Intuitive Surgical | 4.43% | $915.53K | $175.02B | -16.41% | 78 Outperform | |
| Guardant Health | 4.21% | $870.28K | $13.63B | 141.60% | 61 Neutral | |
| Argenx Se | 3.95% | $815.66K | $51.67B | 30.22% | 79 Outperform | |
| HOYA | 3.68% | $761.08K | ¥9.25T | 41.37% | 74 Outperform |
GDOC Technical Analysis
Negative
―
Price Trends
35.75
Negative
34.82
Negative
33.15
Positive
Market Momentum
-0.39
Positive
37.15
Neutral
20.50
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GDOC, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 35.50, equal to the 50-day MA of 35.75, and equal to the 200-day MA of 33.15, indicating a neutral trend. The MACD of -0.39 indicates Positive momentum. The RSI at 37.15 is Neutral, neither overbought nor oversold. The STOCH value of 20.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GDOC.
GDOC Peer Comparison
Comparison Results
Performance Comparison
GDOC
Goldman Sachs Future Health Care Equity ETF
34.42
0.72
2.14%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
OZEM
Roundhill GLP-1 & Weight Loss ETF
―
―
―
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
LGHT
Langar Global HealthTech ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents